Atossa Therapeutics (ATOS +8.7%) is up on increased volume in early trade in reaction to its announcement that
it has started the development of a nasal spray formulation of AT-301
for the potential treatment of newly diagnosed symptomatic COVID-19
patients who are not hospitalized. Clinical studies should commence next
quarter.
The new program is the company’s second in
COVID-19. It is currently developing drug combination AT-H201 for the
treatment of severely ill patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.